HAMBURG, Germany, May 4, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT), (TecDAX) will report its financial results for the first quarter of 2011 on Thursday, 12 May 2011.
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance:
| Conference call details: |
| Date: Thursday, 12 May 2011 |
| Time: |
| 09.30 a.m. CEST |
| 08.30 a.m. BST |
| 03.30 a.m. US time (East Coast) |
| From Europe: |
| +49 (0) 6103 485 3002 (Germany) |
| +44-207-153-2027 (UK) |
| From the US: +1-480-629-9771 |
| Access Code: 4435030 |
A simultaneous slide presentation for participants dialing in via phone is available at www.equitystory.com, password: evotec0511.
Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event.
A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49 69 58 99 90 568 (Germany) or +44 207 154 2833 (UK) and in the US by dialing +1 303 590 3030. The access code is 4435030#. The on-demand version of the webcast will be available on our website: www.evotec.com
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, MedImmune/Astra Zeneca, Novartis, Ono Pharmaceutical and Roche. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include a strategic alliance with Roche for the development of subtype-selective NMDA receptor antagonists for use in treatment-resistant depression as well as other partnerships with Boehringer Ingelheim, MedImmune and with Andromeda (Teva) in the field of diabetes.
For additional information, please go to www.evotec.com.